Africa: Experts Convened By WHO Advise On Candidate Treatments and Vaccines for Ebola Disease Caused By Bundibugyo Virus: [WHO] In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups. These groups assessed potential vaccines and therapeutics for… http://newsfeed.facilit8.network/TSmZm6 #Ebola #BundibugyoVirus #Vaccines #HealthCare #ClinicalTrials
SK Bioscience secures 300 billion won from National Growth Fund to advance Phase 3 trials of GBP410 pneumococcal vaccine, marking first such support for domestic vaccine developer in strategic biotechnology initiative
#YonhapInfomax #SKBioscience #NationalGrowthFund #PneumococcalVaccine #GBP410 #ClinicalTrials #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=122947
Biotech Catalyst Daily — FDA & Clinical Trial Intelligence

The catalyst calendar for investors allocating against FDA decisions.

Burns Media
A double‑blind RCT is testing low‑dose naltrexone (1–4.5 mg) for Post‑COVID Fatigue Syndrome (160 pts, 16 weeks). Sponsored by Luis Nacul (UBC); aims: reduce fatigue, symptoms, inflammatory markers. Details: https://clinicaltrials.gov/study/NCT05430152 🧪🩺 #LongCOVID #PCFS #ClinicalTrials

Full briefing — the morning intelligence for investors and analysts:
https://burns-media.com/biotech/archive/2026-05-22?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_daily

Free. Delivered by 7 AM ET, every weekday.

#Biotech #FDA #Pharma #ClinicalTrials

Burns Media — Intelligence Briefings for Professionals

Daily briefings for the people who bid on federal contracts and write federal grants.

Burns Media
Post-Marketing Surveillance for Biosimilars: Why Approval Is Just the Beginning

Understand the importance of pharmacovigilance and long-term safety monitoring in biosimilar development after regulatory approval.

Full briefing — the morning intelligence for investors and analysts:
https://burns-media.com/biotech/archive/2026-05-21?utm_source=mastodon&utm_medium=social&utm_campaign=biotech_daily

Free. Delivered by 7 AM ET, every weekday.

#Biotech #FDA #Pharma #ClinicalTrials

Burns Media — Intelligence Briefings for Professionals

Daily briefings for the people who bid on federal contracts and write federal grants.

Burns Media

OncoTherapy Science shares struggle amid clinical delays and prolonged investor confidence concerns recently.

#OncoTherapyScience #BiotechStocks #ClinicalTrials #StockMarket

https://meyka.com/blog/oncotherapy-science-stock-slumps-44-in-three-years-on-clinical-delays-2105/

OncoTherapy Science Stock Slumps 44% in Three Years on Clinical Delays | Meyka

4564.T stock trades at ¥20.0 with D+ rating. Biotech firm faces clinical trial headwinds and negative earnings outlook through 2026.

Stem cells have potent potential for diabetes treatment | The-14

Stem cell therapies show promise for Type 1 diabetes by producing insulin cells, with early trials restoring insulin production but challenges remain ahead.

The-14 Pictures